Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. - Wikidata - awgldk - TriplyDB

Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

http://www.wikidata.org/entity/Q37587713

about

Change of paradigm: CD8+ T cells as important helper for CD4+ T cells during asthma and autoimmune encephalomyelitis Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing The development and in vivo function of T helper 9 cells Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells Human Vδ2 T cells are a major source of interleukin-9.Increased circulating IL-9-producing CD8+ T cells are associated with eosinophilia and high FeNO in allergic asthmatics.TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer.Heterogeneity in the differentiation and function of CD8⁺ T cells.Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.Th9 Cells: New Member of T Helper Cell Family.[Th9 cells: a new population of helper T cells].The inducible costimulator augments Tc17 cell responses to self and tumor tissue.Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy.CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.Investigation of the relationship between the Th17/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats.Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells.IL-9 Signaling Pathway: An Update.IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.TGF-β in T Cell Biology: Implications for Cancer Immunotherapy.A conserved enhancer regulates Il9 expression in multiple lineages

P2860

Q26824572-F93D0F4D-F29C-4CDE-B0D8-301B57098D5D Q27334215-76CED874-7876-439F-BA3B-923F0BA4039B Q28083375-BB4F4A5B-FC78-4FE5-A217-1827653144BE Q30399332-66139520-44D0-4D4C-94D7-FECA18BEFAB4 Q34624383-F7078E51-DA6E-4BB2-B0B5-1DD8A569BDB9 Q35129041-3421FB7A-FEEA-44CF-8FDF-1FD1CAD5B5CC Q35946790-A2BCFA3A-7E29-458F-A922-32DE0BDA25EC Q36424657-BCE2F61C-EFFA-400F-BFC1-B7416EFF6D5B Q37166167-3633D01D-369B-4F4A-B7F2-F2D9170A8897 Q37398235-C5E58812-EA57-4246-AEAF-C8EA89DDE979 Q37582185-E70388A6-4F52-4D49-A778-919231D318BF Q37688655-3B8E361A-55EC-46BB-A665-D29C42843BF4 Q38216200-31A4F609-4EB5-46B9-8DA4-C113FC9647FE Q38254639-1341C9E2-4451-48B8-B7AA-B55890494DA7 Q38958004-241A9647-BE00-4423-BD34-1B0C30C53E0B Q40224209-41E36F81-9684-4044-A3FC-F0A2836CE13D Q40690742-700F5B37-B4C7-4DE4-A8AD-6B5E749369F1 Q41551980-D2010B83-7519-40C8-AFF1-801CE075F0E3 Q42146834-E4C6B5C6-2B07-4215-8DC7-4D446D435674 Q42586718-1BB2F802-C807-492D-9BA7-909D69F6EEF7 Q47108861-497AB96C-8407-42C4-84AA-C731D8A1B68F Q47643463-CC79AD7E-15F6-422D-AAD3-35DB38FF1CE2 Q50144881-68451D70-F3CC-4620-A222-B12FA83A4833 Q51744571-2824E6ED-427F-42F1-923E-FC1D8DF22881 Q52658494-9A796C80-926B-44C3-AB3E-D3C4A0C96374 Q53119068-E7F21417-5E64-45FC-ACE8-B15E75BF9BF1 Q54978680-08D27745-06D1-44E9-8015-D1839C634F53 Q55515390-DE2C0276-28D4-4AC1-B407-45F366A24FB1 Q59129129-45536E40-06F6-4DB4-9F49-9BF7ECB499FD

P2860

Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

http://www.wikidata.org/entity/Q37587713

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@en

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@nl

type

label

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@en

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@nl

prefLabel

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@en

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@nl

P1433

Q37587713-B8437FE8-AF08-4698-969C-7549D3F5CE30

P1476

Q37587713-E7C2E274-01E4-4853-B877-0B5BCBECE559

P2093

Q37587713-1E8F4372-6012-48AC-AC8C-55370B3541A4

Q37587713-2CDF8425-2F1F-4939-AAFC-10A49EE7DDDF

Q37587713-353D57B7-E85B-48B0-A88F-86EB69479338

Q37587713-42AF399C-81FB-42F7-9207-13B439BBDA54

Q37587713-64ED05CB-F419-45A1-ABB2-603EDBE63483

Q37587713-B5E249A4-D459-4AB6-8E2D-5B760D8F7521

Q37587713-EDB9D735-5BE0-46FE-B749-973EB938D4A1

Q37587713-F050603B-F56D-46B6-B1C4-94FF03380D6C

P2860

Q37587713-0F1A5292-153A-4B40-AF64-A7C40A530CEB

Q37587713-13BD558D-0928-4801-99EB-7248BEB57A3A

Q37587713-1FD750F4-F1EA-4E73-B8AD-C5336D586A37

Q37587713-323F824F-994D-416D-8F61-D6568726D3F5

Q37587713-33B4B586-C6D8-411A-A097-CBFDC8D6A2B0

Q37587713-428DBAB2-91CC-4384-B7E2-C92FB312CF8D

Q37587713-453B9321-1578-4E4F-B173-D88D4B53A619

Q37587713-4E6FC213-50F2-435F-A240-D845D824ECBF

Q37587713-502CA29D-697D-4FB9-A065-E514063FE34B

Q37587713-5377099F-946C-4D24-81BB-0281DDA58DB9

P304

Q37587713-42E9C0E3-C342-4B7A-94A4-E56830246DEE

P31

Q37587713-19DEE6DF-BE20-4E13-A7FD-5DD092BC3F43

P356

Q37587713-E90B6F80-C29C-448C-8DFE-B056C7B282E1

P407

Q37587713-4E96A8A8-0032-4F8A-9830-1848B8577CE4

P433

Q37587713-0BF0275F-97BC-4500-91CC-F991E91707A8

P478

Q37587713-9F442040-837E-446D-9F95-63CB0A6BBCE5

P577

Q37587713-F315ED1C-C317-4E14-92A9-BEE4D53534BE

P5875

Q37587713-8B76826A-A93C-439A-A23D-16C4624A046F

P698

Q37587713-3825007F-7F05-4EC9-8E48-04886278B520

P921

Q37587713-2798A137-2394-4791-8D28-315301D6B936

Q37587713-A4DE0FB0-E18E-4B68-8532-F7FC43B98CED

P932

Q37587713-8E696659-3F41-4763-B83B-22E96FB82601

P356

PNAS.1317431111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tumor-specific IL-9-producing ...... tive immunotherapy of cancers.

@en

P2093

Bangxing Hong

http://www.w3.org/2001/XMLSchema#string

Haiyan Li

http://www.w3.org/2001/XMLSchema#string

Jianfei Qian

http://www.w3.org/2001/XMLSchema#string

Mingjun Zhang

http://www.w3.org/2001/XMLSchema#string

Qing Yi

http://www.w3.org/2001/XMLSchema#string

Siqing Wang

http://www.w3.org/2001/XMLSchema#string

Yong Lu

http://www.w3.org/2001/XMLSchema#string

Yuhuan Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Adoptive T cell therapy for cancer in the clinic

Adoptive immunotherapy for cancer: harnessing the T cell response

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

A brief history of IL-9

P304

2265-2270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1317431111

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259956497

http://www.w3.org/2001/XMLSchema#string

P698

24469818

http://www.w3.org/2001/XMLSchema#string

P921

P932

3926063

http://www.w3.org/2001/XMLSchema#string